Esperion Therapeutics Company Profile (NASDAQ:ESPR)

About Esperion Therapeutics

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company's lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ESPR
  • CUSIP:
Key Metrics:
  • Previous Close: $13.51
  • 50 Day Moving Average: $11.50
  • 200 Day Moving Average: $14.13
  • 52-Week Range: $9.58 - $30.41
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.84
  • P/E Growth: 0.72
  • Market Cap: $304.65M
  • Outstanding Shares: 22,550,000
  • Beta: 2.03
Profitability:
  • Return on Equity: -19.32%
  • Return on Assets: -18.72%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 27.40%
  • Quick Ratio: 27.40%
Additional Links:
Companies Related to Esperion Therapeutics:

Analyst Ratings

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: $30.92 (128.84% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016Stifel NicolausReiterated RatingBuy$64.00View Rating Details
8/31/2016Barclays PLCSet Price TargetHold$13.00View Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$15.00View Rating Details
7/6/2016Credit Suisse Group AGReiterated RatingSell$10.00View Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00View Rating Details
6/29/2016Chardan CapitalReiterated RatingHold$13.00View Rating Details
6/29/2016Needham & Company LLCReiterated RatingBuy$77.00 -> $25.00View Rating Details
6/29/2016Citigroup Inc.Reiterated RatingBuy$36.00 -> $22.00View Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00View Rating Details
6/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$30.00 -> $15.00View Rating Details
6/16/2016JMP SecuritiesReiterated RatingBuy$67.00View Rating Details
11/6/2015Bank of America Corp.Reiterated RatingBuy$65.00View Rating Details
8/17/2015FIXReiterated RatingaddView Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.48)($0.56)ViewN/AView Earnings Details
3/5/2015($0.54)($0.49)ViewN/AView Earnings Details
8/12/2014Q214$0.60$0.60ViewN/AView Earnings Details
5/12/2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
Current Year EPS Consensus Estimate: $-3.49 EPS
Next Year EPS Consensus Estimate: $-3.52 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.82)($0.82)($0.82)
Q2 20161($0.78)($0.78)($0.78)
Q3 20161($1.02)($1.02)($1.02)
Q4 20161($1.28)($1.28)($1.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Esperion Therapeutics (NASDAQ:ESPR)
Insider Ownership Percentage: 35.40%
Institutional Ownership Percentage: 65.22%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
DateHeadline
News IconBB Biotech Spots Potential In Esperion Therapeutics (ESPR); Tempur Sealy Intl (TPX) Tumbles on Bearish Outlook (NASDAQ:ESPR)
galaxystocks.com - September 28 at 4:44 PM
News IconEsperion Therapeutics Showing Volatility Leading into Clinical Trial Announcement - Minyanville.com (NASDAQ:ESPR)
www.minyanville.com - September 28 at 9:48 AM
News IconEsperion Therapeutics Showing Volatility Leading into Clinical Trial Announcement (NASDAQ:ESPR)
www.minyanville.com - September 27 at 4:55 PM
News IconHot Biotech Stocks Recap: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Esperion Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ESPR)
voiceregistrar.com - September 22 at 10:27 AM
nasdaq.com logoNoteworthy Tuesday Option Activity: ESPR, OPHT, FDS (NASDAQ:ESPR)
www.nasdaq.com - September 21 at 9:05 AM
finance.yahoo.com logoEsperion Therapeutics (ESPR) in Focus: Stock Jumps 18.1% (NASDAQ:ESPR)
finance.yahoo.com - September 21 at 9:05 AM
capitalcube.com logoEsperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016 (NASDAQ:ESPR)
www.capitalcube.com - September 14 at 4:58 PM
News IconBrokers Update Target Prices On Esperion Therapeutics, Inc. (ESPR) - National Daily Press (NASDAQ:ESPR)
www.nationaldailypress.com - September 14 at 9:03 AM
News IconStock Struggling for the Quarter: Esperion Therapeutics, Inc ... - Post News (NASDAQ:ESPR)
www.kentuckypostnews.com - September 4 at 9:22 AM
benzinga.com logoESPR: Insiders vs. Shorts (NASDAQ:ESPR)
www.benzinga.com - August 31 at 4:49 PM
benzinga.com logoESPR: Insiders vs. Shorts (NASDAQ:ESPR)
www.benzinga.com - August 31 at 4:49 PM
finance.yahoo.com logoIs Esperion Therapeutics (ESPR) Stock a Solid Choice Right Now? (NASDAQ:ESPR)
finance.yahoo.com - August 26 at 4:47 PM
News IconStock Tracking Lower for the Quarter: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Post News (NASDAQ:ESPR)
www.kentuckypostnews.com - August 20 at 4:50 PM
News IconMy Watchlist for Friday, August 19 (NASDAQ:ESPR)
ac-investor.blogspot.com - August 19 at 4:51 PM
News IconInstitutions Have Decreased Their Ownership of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Post News (NASDAQ:ESPR)
www.kentuckypostnews.com - August 19 at 6:55 AM
News IconWhat is the Consensus on Esperion Therapeutics, Inc. (NASDAQ ... - Post News (NASDAQ:ESPR)
www.kentuckypostnews.com - August 19 at 6:55 AM
News IconShares Moving Lower Over the Past Month Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Post News (NASDAQ:ESPR)
www.kentuckypostnews.com - August 18 at 6:25 AM
finance.yahoo.com logoESPERION THERAPEUTICS, INC. Financials (NASDAQ:ESPR)
finance.yahoo.com - August 13 at 4:48 PM
sg.finance.yahoo.com logoEsperion Therapeutics reports 2Q loss (NASDAQ:ESPR)
sg.finance.yahoo.com - August 4 at 10:39 PM
twst.com logoEsperion Therapeutics Inc.: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results (NASDAQ:ESPR)
www.twst.com - August 4 at 5:09 PM
publicnow.com logoEsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results (NASDAQ:ESPR)
www.publicnow.com - August 4 at 5:09 PM
News IconHC Stocks Newsbeat: Esperion Therapeutics Inc (NASDAQ:ESPR), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release) (NASDAQ:ESPR)
sharemarketupdates.com - July 28 at 3:37 PM
News IconEsperion Therapeutics Inc Can't Be More Safe. Trades Significantly Higher - Consumer Eagle (NASDAQ:ESPR)
www.consumereagle.com - July 22 at 7:01 AM
News IconEsperion Therapeutics Incorporated (NASDAQ:ESPR) Shorted Shares Decreased By 1.99% - Press Telegraph (NASDAQ:ESPR)
presstelegraph.com - July 21 at 8:26 AM
News IconHow Analysts Rated Esperion Therapeutics Inc (NASDAQ:ESPR) Last Week? - Consumer Eagle (NASDAQ:ESPR)
www.consumereagle.com - July 20 at 7:12 AM
News IconEquity Roundup: Stock Performance Focus on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph (NASDAQ:ESPR)
presstelegraph.com - July 20 at 7:12 AM
News IconIncreased Volatility Noted on Shares of: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Engelwood Daily (NASDAQ:ESPR)
www.engelwooddaily.com - July 17 at 4:34 PM
News IconShares Experiencing a Downtrend: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - TGP (NASDAQ:ESPR)
telanaganapress.com - July 16 at 8:18 AM
equities.com logoEsperion Therapeutics Inc. (ESPR) Jumps 7.52% on July 15 - Equities.com (NASDAQ:ESPR)
www.equities.com - July 16 at 8:18 AM
nasdaq.com logoEsperion Director buys 4,400 shares (NASDAQ:ESPR)
www.nasdaq.com - July 14 at 10:14 PM
News IconInvestor News: Investigation of Esperion Therapeutics Inc (NASDAQ:ESPR) over potential Misconduct (NASDAQ:ESPR)
www.groundreport.com - July 14 at 10:14 PM
news.cmlviz.com logoEsperion Therapeutics Inc Realized Volatility Hits Extreme Level - CML News (NASDAQ:ESPR)
news.cmlviz.com - July 14 at 5:00 PM
News IconInvestor News: Investigation of Esperion Therapeutics Inc (NASDAQ:ESPR) over potential Misconduct - GroundReport (NASDAQ:ESPR)
www.groundreport.com - July 13 at 5:12 PM
fiscalstandard.com logoBroker Outlook For Esperion Therapeutics, Inc. (ESPR) - Fiscal Standard (NASDAQ:ESPR)
www.fiscalstandard.com - July 13 at 5:12 PM
News IconTrading Performance and Target Watch for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph (NASDAQ:ESPR)
presstelegraph.com - July 12 at 9:16 AM
News IconWallachbeth Downgrades Esperion Therapeutics Inc to Hold - TheFounders Daily (NASDAQ:ESPR)
www.thefoundersdaily.com - July 12 at 9:16 AM
benzinga.com logoThese Five Stocks Have Gotten A Lot Of Attention From Analysts (NASDAQ:ESPR)
www.benzinga.com - July 11 at 4:54 PM
News IconCompany Stock Focus for Esperion Therapeutics, Inc. (NASDAQ:ESPR): Which Way Will Shares Head? - Press Telegraph (NASDAQ:ESPR)
presstelegraph.com - July 11 at 9:42 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Esperion Therapeutics, Inc. (ESPR) - Fiscal Standard (NASDAQ:ESPR)
www.fiscalstandard.com - July 10 at 4:40 PM
equities.com logoEsperion Therapeutics Inc. (ESPR) Jumps 6.17% on July 08 - Equities.com (NASDAQ:ESPR)
www.equities.com - July 9 at 8:21 AM
News IconEsperion Therapeutics Inc (NASDAQ:ESPR) Stock Sentiment Improves - Press Telegraph (NASDAQ:ESPR)
presstelegraph.com - July 8 at 4:53 PM
insidermonkey.com logoBeleaguered Esperion Therapeutics Inc. (ESPR) and Two Other Struggling Companies Register Insider Buying - Insider Monkey (blog) (NASDAQ:ESPR)
www.insidermonkey.com - July 8 at 4:53 PM
News IconBeleaguered Esperion Therapeutics Inc. (ESPR) and Two Other Struggling Companies Register Insider Buying (NASDAQ:ESPR)
feedproxy.google.com - July 8 at 11:15 AM
news.cmlviz.com logoEsperion Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News (NASDAQ:ESPR)
news.cmlviz.com - July 8 at 7:26 AM
fiscalstandard.com logoBrokers Issue Average Price Target Of 32.85 On Esperion Therapeutics, Inc. (ESPR) - Fiscal Standard (NASDAQ:ESPR)
www.fiscalstandard.com - July 7 at 10:04 PM
News IconInvestigation for Investors of Esperion Therapeutics Inc (NASDAQ:ESPR) Announced - Digital Journal (NASDAQ:ESPR)
www.digitaljournal.com - July 7 at 4:55 PM
equities.com logoEsperion Therapeutics Inc. (ESPR) is Trading Lower on Unusual Volume for July 05 - Equities.com (NASDAQ:ESPR)
www.equities.com - July 7 at 7:10 AM
News IconInsiders Increasing Positions in: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph (NASDAQ:ESPR)
presstelegraph.com - July 6 at 10:43 PM
News IconStock Rating Watch and Earnings Insight for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph (NASDAQ:ESPR)
presstelegraph.com - July 6 at 9:37 AM
istreetwire.com logoTrend Analysis Report: NorthStar Asset Management (NSAM), Esperion Therapeutics (NASDAQ:ESPR), CME ... - iStreetWire (NASDAQ:ESPR)
istreetwire.com - July 5 at 4:46 PM

Social

Esperion Therapeutics (NASDAQ:ESPR) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff